Prosecution Insights
Prosecution Insights
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 1 | 80.8% | -15.2% |
| ALAWADI, SARAH | 1 | 37.6% | +38.2% |
| HOERNER, PAUL ELLSWORTH | 1 | 49.4% | +63.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277637 | ANTI-CANCER PHARMACEUTICAL COMPOSITION FOR TARGETING HEAT SHOCK PROTEIN 70, CONTAINING INDOLOQUINAZOLIDINE ALKALOID | AULAKH, CHARANJIT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17759220 | GRAPHENE-BASED COMPOSITION FOR TREATING KIDNEY DISEASE | ALAWADI, SARAH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17759220 | GRAPHENE-BASED COMPOSITION FOR TREATING KIDNEY DISEASE | ALAWADI, SARAH | — |
| 17258105 | GRAPHENE QUANTUM DOT AS THERAPEUTIC AGENT FOR DISEASE ASSOCIATED WITH ABNORMAL FIBRILLATION OR AGGREGATION OF NEUROPROTEIN | HOERNER, PAUL ELLSWORTH | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1619 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18277637 | ANTI-CANCER PHARMACEUTICAL COMPOSITION FOR TARGETING HEAT SHOCK PROTEIN 70, CONTAINING INDOLOQUINAZOLIDINE ALKALOID | AULAKH, CHARANJIT | 1621 | §103 | Non-Final OA | — | Pending | Aug 17, 2023 |
| 17759220 | GRAPHENE-BASED COMPOSITION FOR TREATING KIDNEY DISEASE | ALAWADI, SARAH | 1619 | §102§103 | Final Rejection | — | Pending | Jul 21, 2022 |
| 17258105 | GRAPHENE QUANTUM DOT AS THERAPEUTIC AGENT FOR DISEASE ASSOCIATED WITH ABNORMAL FIBRILLATION OR AGGREGATION OF NEUROPROTEIN | HOERNER, PAUL ELLSWORTH | 1611 | §103 | Final Rejection | — | Pending | Apr 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial